Browsing by Author "Latif, Ali"
Now showing items 1-11 of 11
-
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
(2023 , Article)In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ... -
Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
( Massachusetts Medical Society , 2022 , Article)The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ... -
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
( Massachusetts Medical Society , 2022 , Article)Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ... -
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
( Massachusetts Medical Society , 2022 , Article)The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ... -
Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020
( BMJ Publishing Group , 2020 , Article)© Authors 2020 Objective To define the epidemiological curve of COVID-19 in Qatar and determine factors associated with severe or critical illness. Design Case series of first 5685 COVID-19 cases in Qatar. Setting and ... -
Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
( Massachusetts Medical Society , 2022 , Other)More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ... -
Protection against Reinfection with the Omicron BA.2.75 Subvariant
( Massachusetts Medical Society , 2023 , Other)The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) ... -
Protection against the omicron variant from previous SARS-CoV-2 infection
( Massachusetts Medical Society , 2022 , Other)Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ... -
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.
( Massachusetts Medical Society , 2022 , Article)The BA.4 and BA.5 subvariants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant have shown the capacity of escaping from neutralizing antibodies.1 These subvariants had an ... -
Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar
( BMJ Publishing Group , 2023 , Article)Objective To assess the evolution of COVID-19 severity and fatality in a unique setting that consistently applied, throughout the pandemic, rigorous and standardised criteria for defining severe COVID-19 outcomes. Methods ... -
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
( Massachusetts Medical Society , 2021 , Article)Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine ...
